AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25577464 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic excision of ovarian endometrioma (recurrent surgery group)
Number of subjects: 28
Study 24083811 — intervention group
Group type: EXPERIMENTAL
Intervention: New brochure
Number of subjects: 346
Study 24083811 — intervention group
Group type: COMPARATOR
Intervention: Old brochure
Number of subjects: 346
Study 21118410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual non‐parenteral combination therapy (including bosentan, sitaxentan, ambrisentan, iloprost, and sildenafil)
Number of subjects: 112
Study 21118410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual non‐parenteral combination therapy
Number of subjects: 112
Study 19693799 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg alone
Number of subjects: 30
Study 19693799 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 200 mg twice daily
Number of subjects: 30
Study 19693799 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER with trimethoprim
Number of subjects: 30
Study 19693799 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 30
Study 17215422 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 6
Study 17215422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 6
Study 15129943 — intervention group
Group type: EXPERIMENTAL
Intervention: Starplasty tracheotomy (SPT)
Number of subjects: 11
Study 15129943 — intervention group
Group type: COMPARATOR
Intervention: Regular tracheotomy (RT)
Number of subjects: 11
Study 11281672 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine dermal collagen xenograft (Permacol)
Number of subjects: 26
Study 11281672 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy alone (control)
Number of subjects: 26
Study 9755355 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (e.g., selective serotonin reuptake inhibitors)
Number of subjects: 0
Study 9755355 — intervention group
Group type: COMPARATOR
Intervention: Noradrenergic and mixed serotonergic/noradrenergic tricyclic antidepressants
Number of subjects: 0
Study 8050803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate with zero ultrafiltration (group II)
Number of subjects: 16
Study 8050803 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysate with standard ultrafiltration (group I)
Number of subjects: 16
Study 2656781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 16
Study 2656781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31768724 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with laparoscopic hysterectomy module on a virtual reality simulator
Number of subjects: 20
Study 31768724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 20
Study 31444318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathfile (PF) 1 and PF2
Number of subjects: 36
Study 31444318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathfile (PF2)
Number of subjects: 36
Study 31444318 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglider (PG)
Number of subjects: 36
Study 28485007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib plus lenalidomide and dexamethasone (IRd)
Number of subjects: 0
Study 28485007 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lenalidomide and dexamethasone (placebo-Rd)
Number of subjects: 0
Study 26237826 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dachengqi tang (DCQT)
Number of subjects: 60
Study 26237826 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 23522373 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training added to standard care (prevention exercises, quadriceps strengthening, and agility exercises)
Number of subjects: 80
Study 23522373 — intervention group
Group type: COMPARATOR
Intervention: Standard care (prevention exercises, quadriceps strengthening, and agility exercises)
Number of subjects: 80
Study 23522373 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training added to standard care
Number of subjects: 80
Study 23522373 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 21620467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 5 days
Number of subjects: 1004
Study 21620467 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone for 10 days
Number of subjects: 1004
Study 19551680 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular laser photocoagulation (MP) after intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 49
Study 19551680 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular laser photocoagulation (MP) concomitant with intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 49
Study 19551680 — intervention group
Group type: COMPARATOR
Intervention: Only intravitreal injection of 4 mg of triamcinolone acetonide (IVTA)
Number of subjects: 49
Study 19551680 — intervention group
Group type: COMPARATOR
Intervention: Comparison of VA between control and study groups
Number of subjects: 49
Study 16619152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-associated amphotericin B plus Mycograb
Number of subjects: 139
Study 16619152 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B plus placebo
Number of subjects: 139
Study 15127870 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews with direct clinical relevance
Number of subjects: 96
Study 11229943 — intervention group
Group type: EXPERIMENTAL
Intervention: LET (lidocaine, epinephrine, tetracaine)
Number of subjects: 60
Study 11229943 — intervention group
Group type: COMPARATOR
Intervention: EMLA (eutectic mixture of local anesthetics)
Number of subjects: 60
Study 11229943 — intervention group
Group type: EXPERIMENTAL
Intervention: LET
Number of subjects: 60
Study 11229943 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 60
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 2.5 microg
Number of subjects: 80
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 5 microg
Number of subjects: 80
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 10 microg
Number of subjects: 80
Study 9390596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil
Number of subjects: 80
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 80
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups receiving opioids
Number of subjects: 80
Study 9390596 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 8578350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (once-sampled)
Number of subjects: 118
Study 8578350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (multisampled)
Number of subjects: 118
Study 8578350 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant women
Number of subjects: 118
Study 2156476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir, 2.5 mg/kg body weight every 8 hours for 14 days
Number of subjects: 0
Study 2156476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 396054 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 20 mg/kg praziquantel
Number of subjects: 28
Study 396054 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 50 mg/kg praziquantel
Number of subjects: 28
Study 30121774 — intervention group
Group type: COMPARATOR
Intervention: Good glycemic control (HbA1c < 6.5%, FPG < 6.1 mmol/L)
Number of subjects: 1815
Study 30121774 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient glycemic control (HbA1c < 6.5%, FPG ≥ 6.1 mmol/L or HbA1c ≥ 6.5%, FPG < 6.1 mmol/L)
Number of subjects: 1815
Study 30121774 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control (HbA1c ≥ 6.5%, FPG ≥ 6.1 mmol/L)
Number of subjects: 1815
Study 30121774 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient glycemic control
Number of subjects: 1815
Study 30121774 — intervention group
Group type: COMPARATOR
Intervention: Good glycemic control
Number of subjects: 1815
Study 30121774 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-exposed group
Number of subjects: 1815
Study 30121774 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient glycemic control with insulin exposure
Number of subjects: 1815
Study 28501708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 165
Study 28501708 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 165
Study 25918334 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (intervention group)
Number of subjects: 1170
Study 25918334 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1170
Study 24641302 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrobrasion
Number of subjects: 0
Study 24641302 — intervention group
Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 0
Study 23419401 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD) 9 g in tea, taken three times daily for 12 weeks
Number of subjects: 30
Study 23419401 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 30
Study 19744817 — intervention group
Group type: COMPARATOR
Intervention: Internet or interactive computer-based patient education programs
Number of subjects: 2374
Study 17922350 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group training
Number of subjects: 100
Study 17922350 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training
Number of subjects: 100
Study 17922350 — intervention group
Group type: EXPERIMENTAL
Intervention: Formable HPDs
Number of subjects: 100
Study 17922350 — intervention group
Group type: EXPERIMENTAL
Intervention: Premolded HPDs
Number of subjects: 100
Study 16172203 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 to 30 mg per day)
Number of subjects: 1493
Study 16172203 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (8 to 32 mg per day)
Number of subjects: 1493
Study 16172203 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200 to 800 mg per day)
Number of subjects: 1493
Study 16172203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1.5 to 6.0 mg per day)
Number of subjects: 1493
Study 16172203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40 to 160 mg per day)
Number of subjects: 1493
Study 11821268 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonal‐F
Number of subjects: 812
Study 11821268 — intervention group
Group type: EXPERIMENTAL
Intervention: Puregon
Number of subjects: 812
Study 11821268 — intervention group
Group type: COMPARATOR
Intervention: Repeated cycles (both Gonal‐F and Puregon)
Number of subjects: 812
Study 10627844 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast (80%) optotypes
Number of subjects: 30
Study 10627844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast (6%) optotypes
Number of subjects: 30
Study 10627844 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast optotypes with dioptric blur
Number of subjects: 30
Study 10627844 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal and amblyopic eyes tested at threshold
Number of subjects: 30
Study 10627844 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast optotypes
Number of subjects: 30
Study 8867876 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93426 (0.04 mg; 0.04 ml/kg)
Number of subjects: 36
Study 8867876 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg; 1 ml)
Number of subjects: 36
Study 8867876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1363719 — intervention group
Group type: EXPERIMENTAL
Intervention: sulglycotide + H2-antagonists
Number of subjects: 626
Study 1363719 — intervention group
Group type: COMPARATOR
Intervention: sulglycotide alone
Number of subjects: 626
Study 6094445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 3 g intravenously perioperatively
Number of subjects: 167
Study 6094445 — intervention group
Group type: COMPARATOR
Intervention: Control group without prophylactic antibiotics
Number of subjects: 167
Study 29802051 — intervention group
Group type: COMPARATOR
Intervention: Video-based tutorial by a skilled expert (Group A)
Number of subjects: 51
Study 29802051 — intervention group
Group type: COMPARATOR
Intervention: VR training program (Uro-Trainer) (Group B)
Number of subjects: 51
Study 29802051 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-TURBT training
Number of subjects: 51
Study 28329753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (twice a week for 90 min with increasing loads)
Number of subjects: 49
Study 28329753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 49
Study 28329753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 25909233 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-Wise online alcohol prevention program
Number of subjects: 0
Study 24108779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml of DTaP
Number of subjects: 111
Study 24108779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of DTaP
Number of subjects: 111
Study 21435609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 400
Study 21435609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Number of subjects: 400
Study 21435609 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural minimal lumen diameter
Number of subjects: 400
Study 21435609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 400
Study 19666435 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 24
Study 19666435 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 17554217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) 500 mg twice daily or 1000 mg twice daily with ritonavir 100 mg twice daily
Number of subjects: 41
Study 17554217 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TPV/r
Number of subjects: 41
Study 17554217 — intervention group
Group type: COMPARATOR
Intervention: Low-dose TPV/r
Number of subjects: 41
Study 17554217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 41
Study 15132999 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - METPA (weighted metabolic score of intensity, frequency, and duration)
Number of subjects: 0
Study 15132999 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - MECHPA (sum of all ground reaction forces multiplied by duration)
Number of subjects: 0
Study 15132999 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0
Study 15132999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mass measurement in black children (girls only)
Number of subjects: 0
Study 11181397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole for 7 days followed by oral itraconazole solution at 200 mg twice daily for 14 days
Number of subjects: 17
Study 11181397 — intervention group
Group type: COMPARATOR
Intervention: Oral itraconazole solution at 200 mg once daily for 14 days
Number of subjects: 17
Study 11181397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution at 200 mg twice daily for 14 days
Number of subjects: 17
Study 11181397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole for 7 days followed by oral itraconazole solution
Number of subjects: 17
Study 1350340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine with clonidine
Number of subjects: 0
Study 1350340 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo with clonidine
Number of subjects: 0
Study 2863295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 200 mg
Number of subjects: 10
Study 2863295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2863295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (various doses)
Number of subjects: 10
Study 2863295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 10
Study 30829190 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending programme for 1 year
Number of subjects: 124
Study 30829190 — intervention group
Group type: COMPARATOR
Intervention: Information about social activities only (active control)
Number of subjects: 124
Study 29659539 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (1.15 and 0.26 g/kg on game and training days, respectively)
Number of subjects: 20
Study 29659539 — intervention group
Group type: COMPARATOR
Intervention: Energy‐matched placebo (1.37 and 0.31 g/kg of carbohydrate on game and training days, respectively)
Number of subjects: 20
Study 27435082 — intervention group
Group type: COMPARATOR
Intervention: Secondary education
Number of subjects: 70506
Study 27435082 — intervention group
Group type: COMPARATOR
Intervention: Tertiary education
Number of subjects: 70506
Study 24578545 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg citalopram
Number of subjects: 21
Study 24578545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 24578545 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (no medication)
Number of subjects: 21
Study 22534255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg orally once daily for 7 days)
Number of subjects: 24
Study 22534255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg orally once daily for 10 days)
Number of subjects: 24
Study 22534255 — intervention group
Group type: COMPARATOR
Intervention: Gemigliptin monotherapy
Number of subjects: 24
Study 22534255 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration with ketoconazole
Number of subjects: 24
Study 22534255 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration with rifampicin
Number of subjects: 24
Study 20824184 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptotic tumor-autologous dendritic cell vaccine
Number of subjects: 24
Study 18090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (450 mg/day)
Number of subjects: 624
Study 18090504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 16649832 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational groups (8 sessions over 4 to 5 months)
Number of subjects: 236
Study 16649832 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 236
Study 12599083 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT + daily iron
Number of subjects: 546
Study 12599083 — intervention group
Group type: EXPERIMENTAL
Intervention: daily iron
Number of subjects: 546
Study 12599083 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 546
Study 10804679 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manuals and incentives (I)
Number of subjects: 61
Study 10804679 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manuals, incentives, and social support groups (G)
Number of subjects: 61
Study 10804679 — intervention group
Group type: COMPARATOR
Intervention: Self-help manuals (SH)
Number of subjects: 61
Study 8645368 — intervention group
Group type: EXPERIMENTAL
Intervention: picotamide
Number of subjects: 1011
Study 1629387 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 401
Study 1629387 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 401
Study 1629387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 3513329 — intervention group
Group type: EXPERIMENTAL
Intervention: Foaming antacid
Number of subjects: 60
Study 3513329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29618012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg methylphenidate
Number of subjects: 2
Study 29618012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg methylphenidate
Number of subjects: 2
Study 29618012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 27295475 — intervention group
Group type: EXPERIMENTAL
Intervention: Key feature questions during computer-based seminars
Number of subjects: 87
Study 27295475 — intervention group
Group type: COMPARATOR
Intervention: Control condition with long case narratives
Number of subjects: 87
Study 24361242 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ambulatory activity (measured in steps per day)
Number of subjects: 9306
Study 24361242 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ambulatory activity (measured from baseline to 12 months)
Number of subjects: 9306
Study 22961528 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative stimulation settings (pulse frequency of 31 Hz, pulse width of 210 µs)
Number of subjects: 15
Study 22961528 — intervention group
Group type: COMPARATOR
Intervention: Standard setting (pulse frequency of 14 Hz, pulse width of 210 µs)
Number of subjects: 15
Study 21745792 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive levels of US $0, US $5, US $10, and US $20 offered for participation in the follow-up survey.
Number of subjects: 2607
Study 21745792 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive offered (any level)
Number of subjects: 2607
Study 21745792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic participants
Number of subjects: 2607
Study 21745792 — intervention group
Group type: EXPERIMENTAL
Intervention: Men reporting unprotected anal intercourse
Number of subjects: 2607
Study 21745792 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 2607
Study 21745792 — intervention group
Group type: EXPERIMENTAL
Intervention: Email addresses used for online financial management and daily checked email accounts
Number of subjects: 2607